In a nutshell This study evaluated the risk of developing congestive heart failure (CHF; the muscle of the heart becomes weak and does not pump blood efficiently) in patients with non-Hodgkin’s lymphoma (NHL) after first-line chemoimmunotherapy. This study concluded that treatment containing anthracyclines was associated with a significantly higher...
Read MoreIn a nutshell This study evaluated the effectiveness of filgrastim (Neupogen) as compared to original G-CSF treatments lenograstim and pegfilgrastim (Neulasta). The study concluded that filgrastim was as effective as original G-CSF treatments. Some background Low white blood cell counts can occur...
Read MoreIn a nutshell The authors studied the efficacy of taxanes (class of drugs including paclitaxel [Taxol] and docetaxel [Taxotere]) plus bevacizumab (Avastin) with or without capecitabine (Xeloda) in treating metastatic breast cancer. Some background Bevacizumab has been studied for the treatment of breast cancer that is metastatic (that...
Read MoreIn a nutshell In this study researchers examined the effect of a specific chemotherapy combination on disease-free survival in patients with node negative breast cancer. FAC treatment was compared to FAC treatment plus paclitaxel (FACwP). Some background A combination of the drugs fluorouracil (efudex), doxorubicin (doxil), and cyclophosphamide...
Read More
In a nutshell The aim of this article was to determine if the initial shrinking of tumors due to combined chemotherapy is correlated with overall survival (OS) in patients with metastatic breast cancer (MBC – spread to other organs). Some background OS (survival at the end of the treatment) is the best parameter to evaluate treatment...
Read More
In a nutshell This study investigated the use of the chemotherapy regimen known as FOLFIRI with or without the addition of Aflibercept (Zaltrap) to treat metastatic colorectal cancer. Results showed that adding Aflibercept significantly increased the length of time patients survive and the length of time they survive without any disease...
Read More
This article presents results of recent studies concerning the interplay between the body's chemistry and behavioral factors that influence colorectal cancer (CRC) recurrence. Recent advances in CRC treatment have produced new and promising biological treatments. However, tumors sometimes have unique features that render many of these therapies...
Read More
This paper reviews chemotherapy options for triple-negative breast cancers. Breast cancer cells express 3 main receptors that can be targeted with therapy: Estrogen receptors (ER), Progesterone receptors (PR) and HER2. Triple-negative breast cancers (TNBCs) do not express these 3 receptors and make up approximately 15% of breast cancers. Such tumors do...
Read More
